PORTLAND, Ore., May 4 /PRNewswire-FirstCall/ -- Bioject Medical
Technologies Inc., (Nasdaq: BJCT), a leading developer of needle-free drug
delivery systems, announced today that the Company will report its
financial results for the first quarter ended March 31, 2007 on Wednesday,
May 9, 2007, after the close of the financial markets. Management will
conduct a conference call on Thursday, May 10, 2007 at 10:00 a.m. Eastern
Time to review the results for the quarter. Jerald Cobbs, Chairman and
Interim CEO and President, Dr. Rick Stout, EVP and Chief Medical Officer
and Chris Farrell, Vice President of Finance, will be hosting the call.
Live audio of the conference call will be simultaneously broadcast over
the Internet and will be available to investors, members of the news media
and the general public. To participate in the call via telephone, please
dial 1-877-407-8037, or to access the call live over the Internet, visit
Bioject's website at http://www.bioject.com and click on the Investor Relations
section, then on the event icon. A conference call replay will also be
available until May 17, 2007. To listen to the replay, please dial
1-877-660-6853 replay account number 7303, identification number 241095.
Bioject Medical Technologies Inc., based in Portland, Oregon, is an
innovative developer and manufacturer of needle-free drug delivery systems.
Needle-free injection works by forcing medication at high speed through a
tiny orifice held against the skin. This creates a fine stream of
high-pressure fluid penetrating the skin and depositing medication in the
tissue beneath. The Company is focused on developing mutually beneficial
agreements with leading pharmaceutical, biotechnology, and veterinary
companies.
For more information about Bioject, visit: http://www.bioject.com.
SOURCE Bioject Medical Technologies Inc.
 back to top
Related links:
http://www.bioject.com/
CONTACT:
Jerald S. Cobbs, Chairman and Interim CEO and
President, +1-503-692-8001, ext. 4137, or Chris Farrell, Vice
President of Finance, +1-503-692-8001, ext. 4132, both of Bioject
Medical Technologies Inc.
|
